Year: 2007
Type: editorial
Abstract: The aim of this annual review issue of Histopathology is to provide a range of articles addressing diagnostic, predictive and prognostic breast pathology, as well as some overviews of areas of research that have implications for future developments particularly in targeted clinical therapies. A number of the manuscripts address lesions causing diagnostic difficulties, as evidenced by routine day-to-day and referral practice, as reported previously in this journal.1 The lesions selected for review include those that are uncommon but where there are clinically important differential diagnoses, such as the vascular lesions in the breast (CM Brodie and E Provenzano). Others include generally common processes, but where occasional cases cause significant diagnostic difficulty, such as the apocrine lesions (A Bane and FP O’Malley). The group of stromal cell lesions (AHS Lee) includes some lesions in both the above categories; distinguishing the (common) cellular fibroadenoma from the (rare) benign phyllodes tumour may on occasions be difficult, but periductal stromal tumours invariably so, at least in part cause difficulties because of their rarity. Reviews of other, commoner lesions have been selected where there have been developments in understanding of the biology or changes in classification. These include papillary lesions, addressed by LC Collins and SJ Schnitt. These authors’ findings in ‘intracystic’/’encysted’ papillary carcinoma have important implications for routine histological reporting and particularly for clarity of communication within multidisciplinary teams.2 We now recognise that these encapsulated papillary lesions are not truly ‘in situ’ but, as the authors themselves indicate, should be ‘managed in a manner similar to DCIS’. Columnar cell lesions have been described in the medical literature for many years, but it is only in the last 10 years that an association with microcalcification has been recognised.3 The biological and clinical significance, of some forms of these lesions, remains unclear. Nevertheless, the terminology and classification has been amended several times4 and L Feeley and C Quinn not only review the diagnostic features and outline these changes in terminology, but also describe the present understanding of the significance of these lesions. Specific sub-types of carcinoma are addressed in two manuscripts in this issue; one, on lobular carcinoma (A Hanby), includes a review of lobular in situ neoplasia and the present understanding of its clinical significance, including the diagnostically and clinically challenging pleomorphic variant. JS Reis-Filho and A Tutt address the histological and biological characteristics of basal-like and so called ‘triple negative’ cancers and outline the similarities and differences in these (non-equivalent) entities, along with a description of the role of the BRCA1 pathway and the challenges for clinical management, given the lack of any targeted therapy at present in these patients. The ongoing revolution in breast cancer treatment and the clinical aim of identifying individualised targeted therapy for each patient/tumour is reliant on the quality of test for the target molecule. SJL Payne, RL Bowen, JL Jones and CA Well provide an overview of the established role of hormone receptor and HER-2 status assessment in patient management, highlighting the need for standardisation and validation of tests. Participation in UK National External Quality Assessment Scheme (NEQAS) for Immunocytochemistry (for hormone receptors and HER-2) and NEQAS FISH (for in situ hybridisation for HER-2) is clearly mandatory; the role of these invaluable organisations will no doubt expand with future drug developments. D Faratian and J Bartlett highlight the preponderance of tissue biomarkers promising to predict response to therapy in breast cancer patients and outline the more likely candidates for application in breast cancer in the future. They explore the considerations that must be addressed for any new such candidate biomarkers. There is an enormous research interest at present in the role of stem cells in solid malignancies and this line of investigation also has immense implications for the development of tailored treatments. M Cariati and AD Purushotham provide a review of the present evidence-base for the existence of pluripotent mammary epithelial stem cells and in breast cancer stem cells and the mechanisms for investigation of these elusive cells. Molecular and genetic profiling could, potentially, replace some elements of histopathological assessment in the future, particularly for predicting response to treatment and/or prognosis. E Rakha, ME El-Sayed, JS Reis-Filho and IO Ellis outline approaches for applying these techniques in the research setting and the potential impact on patient management of gene expression profiling of breast cancer. They describe why they believe that the molecular-based clinical management of breast cancer requires further investigation and validation, and why the histological and the gene signature approaches to prognostication and prediction of response to therapy are complementary. I have found reading and editing the articles in this review issue of Histopathology both illuminating and educational. I hope the readers, similarly, find the selection of topics stimulating and valuable. I would like to thank all the authors who have contributed their time and expertise.
Source: Histopathology
Author: Sarah E Pinder
Institutions: Guy's Hospital, King's College London
Language: Spanish
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2427892910
